CellSource Co

CellSource Co EBIT Growth

The Year-over-Year EBIT Growth of CellSource Co (4880.T) as of Nov 4, 2026 is 27.75 %. In the previous year, Year-over-Year EBIT Growth was -89.66 % — a change of -130.95% (higher).

EBIT Growth

27.75 %

YoY

-130.95%

Last updated:

Year-over-Year EBIT Growth of CellSource Co is 2025 27.75 % . Year-over-Year EBIT Growth of CellSource Co was 2024 -89.66 % . It decreases by -130.95% higher compared to the previous year.

The CellSource Co EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
85.41 JPY
Jan 1, 2019
10.79 JPY
Jan 1, 2020
27.10 JPY
Jan 1, 2021
139.02 JPY
Jan 1, 2022
58.18 JPY
Jan 1, 2023
-19.65 JPY
Jan 1, 2024
-89.66 JPY
Jan 1, 2025
27.75 JPY
The CellSource Co EBIT Growth history
YEAREBIT GrowthYoY
27.75 %-130.95%
-89.66 %+356.31%
-19.65 %-133.77%
58.18 %-58.15%
139.02 %+412.96%
27.10 %+151.09%
10.79 %-87.36%
85.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Year-over-Year EBIT Growth of CellSource Co is 27.75 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth CellSource Co since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's CellSource Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — CellSource Co

All Key Metrics — CellSource Co